Sustainable financing of a new vaccine's introduction or of a national immunisation programme is a hot topic. It is especially key to understand how an investment case can help getting the required government funding.

In our latest Q&A Series, we have talked with representatives from Egypt, Morocco and Tunisia about their experience with the Rotavirus, PCV and HPV vaccines. As the three countries are all in different stages of the introduction process, they share about the barriers to sustainable financing that they are facing, as well as their best practices on building an investment case.

This is the French translation of the original English Q&A.